1. Home
  2. CELU vs ATNM Comparison

CELU vs ATNM Comparison

Compare CELU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$0.44

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$1.04

Market Cap

31.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CELU
ATNM
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
31.4M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
CELU
ATNM
Price
$0.44
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $4.50
AVG Volume (30 Days)
182.4K
★ 233.5K
Earning Date
12-01-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.17
EPS
0.04
★ 0.53
Revenue
★ $26,550,000.00
$90,000.00
Revenue This Year
$165.42
$29,066.67
Revenue Next Year
$305.36
N/A
P/E Ratio
$11.70
★ $2.06
Revenue Growth
N/A
★ 11.11
52 Week Low
$0.46
$0.74
52 Week High
$2.55
$1.72

Technical Indicators

Market Signals
Indicator
CELU
ATNM
Relative Strength Index (RSI) 25.58 35.22
Support Level N/A $0.91
Resistance Level $0.83 $1.21
Average True Range (ATR) 0.10 0.14
MACD -0.01 -0.06
Stochastic Oscillator 6.38 7.30

Price Performance

Historical Comparison
CELU
ATNM

About CELU Celularity Inc.

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: